Obesity and Energy Substrate Transporters in Ovarian Cancer-Review.
Marta BaczewskaKlaudia BojczukAdrian KołakowskiJakub DobrochPaweł GuzikPaweł KnappPublished in: Molecules (Basel, Switzerland) (2021)
Ovarian cancer is the seventh most common cancer in women. It is characterized by a high mortality rate because of its aggressiveness and advanced stage at the time of diagnosis. It is a nonhomogenous group of neoplasms and, of which the molecular basics are still being investigated. Nowadays, the golden standard in the treatment is debulking cytoreductive surgery combined with platinum-based chemotherapy. We have presented the interactions and the resulting perspectives between fatty acid transporters, glucose transporters and ovarian cancer cells. Studies have shown the association between a lipid-rich environment and cancer progression, which suggests the use of correspondent transporter inhibitors as promising chemotherapeutic agents. This review summarizes preclinical and clinical studies highlighting the role of fatty acid transport proteins and glucose transporters in development, growth, metastasizing and its potential use in targeted therapies of ovarian cancer.
Keyphrases
- fatty acid
- papillary thyroid
- squamous cell
- type diabetes
- minimally invasive
- metabolic syndrome
- blood glucose
- insulin resistance
- polycystic ovary syndrome
- stem cells
- risk factors
- cardiovascular events
- cardiovascular disease
- lymph node metastasis
- high resolution
- squamous cell carcinoma
- blood pressure
- adipose tissue
- combination therapy
- physical activity
- young adults
- mass spectrometry
- single molecule
- case control
- bone marrow
- coronary artery disease
- high fat diet induced
- percutaneous coronary intervention